Home
>
US Stocks
>
Biocryst Pharmaceuticals Inc.
Biocryst Pharmaceuticals Inc.
BCRX

Biocryst Pharmaceuticals Inc.

$15.141.3%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
15.21
Today Low/High
15.14 / 15.52
52 Week Low/High
$3.3 / $18.48
P/E ratio
-12.0143
Market Cap
$2.57B

Company Details

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.
Organisation
Biocryst Pharmaceuticals Inc.
Headquaters
Durham, North Carolina, US
Employees
246
Industry
Health Technology
CEO
Jon Stonehouse

Discover more

Frequently Asked Questions

What is Biocryst Pharmaceuticals Inc. share price today

Can Indians buy Biocryst Pharmaceuticals Inc. shares?

How can I buy Biocryst Pharmaceuticals Inc. shares from India?

Can Fractional shares of Biocryst Pharmaceuticals Inc. be purchased?

What are the documents required to start investing in Biocryst Pharmaceuticals Inc. stocks?

We are a SEBI registered investement advisor